文献速递肿瘤 PET/CT核素与放射性配体治疗

肽探针99mTc-HYNIC-H10F在曲妥珠单抗治疗期间对乳腺癌HER2表达的显像与监测

Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-13

本研究开发了新型分子影像探针99mTc-HYNIC-H10F,用于通过SPECT显像乳腺癌HER2表达以进行患者筛选和曲妥珠单抗疗效监测。在小鼠模型中,该探针在HER2阳性SK-BR3肿瘤中清晰显像,而在HER2阴性MDA-MB-231肿瘤中信号低得多;SPECT/CT在治疗后第4天即反映治疗反应,早于第11天的肿瘤生长抑制。初步临床研究在两名乳腺癌患者中检测到肿瘤HER2表达。

要点

  • 99mTc-HYNIC-H10F在HER2阳性肿瘤中特异性聚集,HER2阴性肿瘤信号低。
  • 该探针与曲妥珠单抗结合HER2抗原的不同结构域。
  • SPECT/CT在治疗后第4天反映治疗反应,早于第11天的肿瘤生长抑制。

核心结论

  • 99mTc-HYNIC-H10F特异性聚集于HER2阳性肿瘤,与曲妥珠单抗结合HER2抗原的不同结构域,为在曲妥珠单抗治疗前、中、后监测HER2表达水平以进行更有效的个体化治疗提供了新机会。

研究设计与样本

  • 研究采用优化方案将H10F肽与99mTc标记制备99mTc-HYNIC-H10F。
  • 在分别荷HER2阳性SK-BR3和HER2阴性MDA-MB-231人乳腺癌异种移植瘤的小鼠模型中进行生物分布和SPECT/CT显像。
  • 在两种HER2阳性乳腺癌模型(SK-BR3和MDA-MB-361)中通过SPECT/CT监测和量化曲妥珠单抗治疗反应。
  • 初步临床研究在两名乳腺癌患者中进行。

主要发现

  • SPECT/CT显示SK-BR3肿瘤清晰显像,而MDA-MB-231肿瘤信号低得多。
  • 99mTc-HYNIC-H10F的肿瘤摄取可被过量未标记H10F肽阻断,但不被过量曲妥珠单抗阻断。
  • 两种HER2阳性肿瘤的生长在治疗后第11天被显著抑制,而SPECT/CT在治疗后第4天即反映治疗反应。
  • 乳腺癌患者肿瘤中的HER2表达可通过99mTc-HYNIC-H10F SPECT/CT显像检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The novel molecular imaging probe 99mTc-HYNIC-H10F was developed for patient screening and efficacy monitoring of trastuzumab therapy by SPECT imaging of HER2 expression in breast cancer. METHODS: 99mTc-HYNIC-H10F was developed by labeling H10F peptide with 99mTc following an optimized protocol. Biodistribution and SPECT/CT were performed in mouse models bearing HER2-positive SK-BR3 and HER2-negative MDA-MB-231 human breast cancer xenografts, respectively. The treatment response to trastuzumab was monitored and quantified by SPECT/CT in two HER2-positive breast cancer models (SK-BR3 and MDA-MB-361). The preliminary clinical study was performed in two patients with breast cancer. RESULTS: SPECT/CT with 99mTc-HYNIC-H10F showed that the SK-BR3 tumors were clearly visualized, while the signals from MDA-MB-231 tumors were much lower. The tumor uptake of 99mTc-HYNIC-H10F could be blocked by excess unlabeled H10F peptide but not by excess trastuzumab. The growth of two HER2-positive tumors was prominently suppressed at day 11 post-treatment. However, SPECT/CT reflected much earlier therapy response at day 4 post-treatment. The HER2 expression in tumors of breast cancer patients could be detected by 99mTc-HYNIC-H10F SPECT/CT imaging. CONCLUSIONS: 99mTc-HYNIC-H10F specifically accumulates in HER2-positive tumors. Compared with trastuzumab, 99mTc-HYNIC-H10F binds to a different domain of HER2 antigen, providing new opportunities to monitor HER2 expression levels before/during/after trastuzumab treatment for more effective personalized treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu Y, Li L, Wang Z, et al. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F. Eur J Nucl Med Mol Imaging. 2020. PMID: 32170344. doi:10.1007/s00259-020-04754-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。